



---

**FOR IMMEDIATE RELEASE**

**China FDA has Approved Zingo® for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial**

**Hong Kong, March 9, 2017, Lee's Pharmaceutical Holdings Limited** ("Lee's Pharm" or the "Group", Stock Code: 950) an integrated research-driven and market-oriented pharmaceutical group in China is pleased to announce that Zingo®, the FDA approved product manufactured by Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, has been granted by China Food and Drug Administration (CFDA) priority review for its clinical trial application.

"We are pleased that CFDA has granted Zingo®, a pediatric use needle-free local analgesia product with priority review for its clinical trial application," said Dr. Benjamin Li, Chief Executive Officer of the Group. "The priority review status is a recognition of Zingo® unique delivery platform technology that addresses a significant unmet medical need for pediatric patients. We hope to move the clinical program rapidly and expect to have the product approved by CFDA in 2018 so that Chinese needle phobic children can benefit from this novel needle-free local analgesia."

**About Zingo®**

Zingo® (lidocaine hydrochloride monohydrate) is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3–18 years of age and to provide topical local analgesia prior to venipuncture in adults. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo® versus a placebo system. Zingo® is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. It is not to be used around the eyes or on body orifices, mucous membranes, or on areas with a compromised skin barrier.

**About Powder Pharmaceuticals, Incorporated ("Powder")**

Powder is an associated company of Lee's Pharmaceutical Holdings Limited based in Hong Kong and is developing products that utilize a proprietary needleless, painless, powder delivery technology and other medical devices. Powder intends to supply Zingo® globally through international business partners. Powder has successfully obtained approval from U.S. FDA in July 2013 for the manufacturing facilities in Hong Kong to produce Zingo® and market the product to U.S.

## **About Lee's Pharmaceutical Holdings Limited ("Lee's Pharm")**

Lee's Pharm is a research-based Hong Kong biopharmaceutical company listed in Hong Kong with more than 20 years of operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with more than 20 international companies and currently has 15 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. The company's development program is lauded with over 40 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies, including promising compounds to treat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharm is available at [www.leespharm.com](http://www.leespharm.com).

### **Safe Harbour Statement**

*The performance and the results of operation of Lee's Pharm during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's Pharm. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's Pharm nor the Directors, employees or agents of Lee's Pharm assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialize or turns out to be incorrect.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*